IL-32θ negatively regulates IL-1β production through its interaction with PKCδ and the inhibition of PU.1 phosphorylation

FEBS Lett. 2014 Aug 25;588(17):2822-9. doi: 10.1016/j.febslet.2014.06.029. Epub 2014 Jul 1.

Abstract

It has been well known that IL-32 exerts pro-inflammatory effects on the various inflammatory diseases in clinical studies. Here, we confirmed that IL-32θ, a new isoform of IL-32, decreased the phorbol 12-myristate 13-acetate (PMA)-induced IL-1β expression in THP-1 human myelomonocyte. We previously reported that the IL-32 isoforms control expressions of other cytokines via novel PKCs. Likewise, IL-32θ interacted with PKCδ, and consequently inhibited PKCδ-mediated phosphorylation of PU.1. Moreover, IL-32θ attenuated the localization of PU.1 into the IL-1β promoter region. These findings reveal that IL-32θ reduces PKCδ-mediated phosphorylation of PU.1, resulting in attenuation of IL-1β production.

Keywords: Interleukin-1β; Interleukin-32; PKCδ; PU.1; THP-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Enzyme Activation / drug effects
  • HEK293 Cells
  • Humans
  • Interleukin-1beta / biosynthesis*
  • Interleukin-1beta / genetics
  • Interleukins / metabolism*
  • Phorbol Esters / pharmacology
  • Phosphorylation / drug effects
  • Promoter Regions, Genetic / drug effects
  • Promoter Regions, Genetic / genetics
  • Protein Binding / drug effects
  • Protein Kinase C-delta / metabolism*
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins / metabolism*
  • Trans-Activators / genetics
  • Trans-Activators / metabolism*
  • Transcriptional Activation / drug effects

Substances

  • IL32 protein, human
  • Interleukin-1beta
  • Interleukins
  • Phorbol Esters
  • Proto-Oncogene Proteins
  • Trans-Activators
  • proto-oncogene protein Spi-1
  • phorbol-12-myristate
  • Protein Kinase C-delta